{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:08:56Z","timestamp":1788473336353,"version":"build-2803163510"},"reference-count":54,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,7,15]]},"DOI":"10.2169\/internalmedicine.6154-25","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:08:07Z","timestamp":1765404487000},"page":"1878-1886","source":"Crossref","is-referenced-by-count":2,"title":["Preventive Effectiveness of Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors"],"prefix":"10.2169","volume":"65","author":[{"given":"Yusuke","family":"Tabata","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Tanimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuma","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Matsuhashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Tanimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Koike","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kojima M, Nakayama T, Tsutani K, et al. Epidemiological characteristics of rheumatoid arthritis in Japan: prevalence estimates using a nationwide population-based questionnaire survey. Mod Rheumatol 30: 941-947, 2020.","DOI":"10.1080\/14397595.2019.1682776"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82: 3-18, 2023.","DOI":"10.1136\/ard-2022-223356corr1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kawahito Y, Morinobu A, Kaneko Y, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis - secondary publication. Mod Rheumatol 33: 21-35, 2023.","DOI":"10.1093\/mr\/roac017"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367: 508-519, 2012.","DOI":"10.1056\/NEJMoa1112072"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376: 652-662, 2017.","DOI":"10.1056\/NEJMoa1608345"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fleischmann RM, Genovese MC, Enejosa JV, et al. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 78: 1454-1462, 2019.","DOI":"10.1136\/annrheumdis-2019-215764"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Combe B, Kivitz A, Tanaka T, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 80: 848-858, 2021.","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 65: 854-861, 2013.","DOI":"10.1002\/acr.21928"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57: 1431-1438, 2007.","DOI":"10.1002\/art.23112"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Singer D, Thompson-Leduc P, Poston S, et al. Incidence of herpes zoster in patients with rheumatoid arthritis in the United States: a retrospective cohort study. J Rheumatol 50: 873-880, 2023.","DOI":"10.3899\/jrheum.220986"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakajima A, Urano W, Inoue E, Taniguchi A, Momohara S, Yamanaka H. Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Mod Rheumatol 25: 558-561, 2015.","DOI":"10.3109\/14397595.2014.984829"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 9: 21-26, 2010.","DOI":"10.1586\/erv.10.30"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol 24: 494-500, 2012.","DOI":"10.1016\/j.coi.2012.06.002"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kawai K, Gebremeskel BG. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 4: e004833, 2014.","DOI":"10.1136\/bmjopen-2014-004833"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Schub D, Assmann G, Sester U, Sester M, Schmidt T. VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Res Ther 20: 252, 2018.","DOI":"10.1186\/s13075-018-1742-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rondaan C, de Haan A, Horst G, et al. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheumatol 66: 3122-3128, 2014.","DOI":"10.1002\/art.38804"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis 7: ofaa005, 2020.","DOI":"10.1093\/ofid\/ofaa005"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80: 304-311, 2021.","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 66: 2675-2684, 2014.","DOI":"10.1002\/art.38745"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Harigai M, Takeuchi T, Smolen JS, et al. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials. Mod Rheumatol 30: 36-43, 2020.","DOI":"10.1080\/14397595.2019.1583711"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Genovese MC, Greenwald MW, Gutierrez-Ure\u00f1a SR, et al. Two-year safety and effectiveness of peficitinib in moderate-to-severe rheumatoid arthritis: a phase IIb, open-label extension study. Rheumatol Ther 6: 503-520, 2019.","DOI":"10.1007\/s40744-019-00167-6"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takeuchi T, Tanaka Y, Tanaka S, et al. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. Rheumatol Ther 8: 425-442, 2021.","DOI":"10.1007\/s40744-021-00280-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Winthrop KL, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Ann Rheum Dis 81: 184-192, 2022.","DOI":"10.1136\/annrheumdis-2021-221051"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Ishiguro N, Tanaka Y, Matsubara T, et al. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years. Mod Rheumatol 33: 64-72, 2022.","DOI":"10.1093\/mr\/roac020"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372: 2087-2096, 2015.","DOI":"10.1056\/NEJMoa1501184"},{"key":"26","unstructured":"26. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581, 2010."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 375: 1019-1032, 2016.","DOI":"10.1056\/NEJMoa1603800"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34: 3661-3679, 2015.","DOI":"10.1002\/sim.6607"},{"key":"29","unstructured":"29. Orenstein WA, Bernier RH, Dondero TJ, et al. Field evaluation of vaccine efficacy. Bull World Health Organ 63: 1055-1068, 1985."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.","DOI":"10.1038\/bmt.2012.244"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Yawn BP, Gilden D. The global epidemiology of herpes zoster. Neurology 81: 928-930, 2013.","DOI":"10.1212\/WNL.0b013e3182a3516e"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 81: 2053-2058, 2009.","DOI":"10.1002\/jmv.21599"},{"key":"33","unstructured":"33. Yabe M, Misaki K, Okada T, et al. The efficacy and safety of an adjuvanted herpes zoster subunit vaccine in rheumatoid arthritis patients treated with JAK inhibitots: a single-center, retrospective analysis in Japan. Clin Rheumatol Rel Res 36: 93-101, 2024."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Ikematsu H, Yamashita N, Ogawa M, Hirano M, Kovac M, Watanabe D. Efficacy, safety and immunogenicity of a novel adjuvanted subunit herpes zoster vaccine in Japanese aged 50 years and 70 years and older. Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 92: 103-114, 2018.","DOI":"10.11150\/kansenshogakuzasshi.92.103"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Bastidas A, de la Serna J, Idrissi ME, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 322: 123-133, 2019.","DOI":"10.1001\/jama.2019.9053"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Mbinta JF, Nguyen BP, Awuni PMA. Post-licensure zoster vaccine effectiveness against herpes zoster and postherpetic neuralgia in older adults: a systematic review and meta-analysis. Lancet Healthy Longev 3: e263-e275, 2022.","DOI":"10.1016\/S2666-7568(22)00039-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Izurieta HS, Wu X, Forshee R, et al. Recombinant zoster vaccine (shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis 73: 941-948, 2021.","DOI":"10.1093\/cid\/ciab125"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. K\u00e4llmark H, Bergstr\u00f6m T, Nagel J, et al. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford) 63: 2024-2033, 2024.","DOI":"10.1093\/rheumatology\/kead552"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Sen N, Sung P, Panda A, Arvin AM. Distinctive roles for type I and type II interferons and interferon regulatory factors in the host cell defense against varicella-zoster virus. J Virol 92: e01151-18, 2018.","DOI":"10.1128\/JVI.01151-18"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Shakya AK, O'Callaghan DJ, Kim SK. Interferon gamma inhibits varicella-zoster virus replication in a cell line-dependent manner. J Virol 93: e00257-19, 2019.","DOI":"10.1128\/JVI.00257-19"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis 80: 865-875, 2021.","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Xu Q, He L, Yin Y. Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis. Front Pharmacol 14: 1241954, 2023.","DOI":"10.3389\/fphar.2023.1241954"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188: 1336-1344, 2003.","DOI":"10.1086\/379048"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Sadaoka K, Okamoto S, Gomi Y, et al. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-\u03b3 enzyme-linked immunospot assay. J Infect Dis 198: 1327-1333, 2008.","DOI":"10.1086\/592219"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 200: 1068-1077, 2009.","DOI":"10.1086\/605611"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Laing KJ, Ouwendijk WJD, Koelle DM, Verjans GMGM. Immunobiology of varicella-zoster virus infection. J Infect Dis 218: S68-S74, 2018.","DOI":"10.1093\/infdis\/jiy403"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Steain M, Sutherland JP, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol 88: 2704-2716, 2014.","DOI":"10.1128\/JVI.03445-13"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 70: 785-791, 2011.","DOI":"10.1136\/ard.2010.128637"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Weaver A, Troum O, Hooper M, et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in RADIUS 1. J Rheumatol 40: 1275-1281, 2013.","DOI":"10.3899\/jrheum.121288"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Cito A, Fornaro M, Carenza A, Anelli MG, Scioscia C, Iannone F. Turning the tide against herpes zoster in rheumatoid arthritis patients treated with JAK inhibitors. J Clin Med 13: 4423, 2024.","DOI":"10.3390\/jcm13154423"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Liao TL, Chen YM, Liu HJ, Chen DY. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia. BMJ Open 7: e014032, 2017.","DOI":"10.1136\/bmjopen-2016-014032"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Redeker I, Albrecht K, Kekow J, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 81: 41-47, 2022.","DOI":"10.1136\/annrheumdis-2021-220651"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Luo Q, Ye J, Zeng L, et al. Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. Mol Med Rep 17: 3297-3305, 2018.","DOI":"10.3892\/mmr.2017.8204"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1\/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 62: 1870-1880, 2010.","DOI":"10.1002\/art.27500"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_6154-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:26:24Z","timestamp":1784345184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/14\/65_6154-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":54,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6154-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"6154-25"}}